

S1 Table. Treatment and clinical endpoints according to the high-flow oxygen support (invasive or non-invasive ventilation, nasal high-flow cannula or non-rebreathing oxygen mask with reservoir).

	Overall (N=430)	High-flow oxygen support		p value
		Yes (N=135)	No (N=295)	
Antiviral treatment				
None	38 (8.8%)	11 (8.1%)	27 (9.2%)	0.961
Lopinavir/R (LPV/R)	3 (0.7%)	1 (0.7%)	2 (0.7%)	
Hydroxychloroquine (HCQ)	96 (22.3%)	32 (23.7%)	64 (21.7%)	
LPV/R + HCQ	293 (68.1%)	91 (67.4%)	202 (68.5%)	
Tocilizumab	120 (27.9%)	84 (62.2%)	36 (12.2%)	<0.001
Pulses of corticoids*	53 (12.3%)	38 (28.1%)	15 (5.1%)	<0.001
Days from admission to high-flow oxygen support	2.3±3.2	3.4±3.4	---	---
Days of hospitalization	12.2±10.4	25.3±13.2	8.0±3.8	<0.001
Overall mortality rate	34 (7.9%)	30 (22.2%)	4 (1.4%)	<0.001
Mortality rate due to covid-19	24 (5.6%)	21 (15.6%)	3 (1%)	<0.001
Readmission related to covid-19 complications	15 (3.5%)	3 (3.1%)	12 (4.3%)	0.428

*Defined as ≥ 1 mg/Kg/d for at least 3 days.